The Glucose-Lowering Potential of Exenatide Delivered Orally via Goblet Cell- Targeting Nanoparticles

Li, Xiang; Wang, Chenhui; Liang, Rongcai; Sun, Fengying; Shi, Yanan; Wang, Aiping; Liu, Wanhui; Sun, Kaoxiang; Li, Youxin

doi:10.1007/s11095-014-1513-1

Cited by 33 publications

(24 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vivo efficacy studies in diabetic rats demonstrated that insulin-loaded CSK-TMC-NPs had significantly higher hypoglycemic effect than achieved with unmodified TMC NPs [177]. Similar observations have been reported for Exendin-4-loaded CSK-TMC-NPs [178]. Although these studies demonstrated that goblet cell targeting ligands could improve oral absorption of insulin in rodents, more studies need to be carried out to critically evaluate the potential of goblet cell targeting.…”

Section: Recent Developments In Targeting Oral Nanoparticles To Spsupporting

confidence: 52%

Nanoparticles for oral delivery: Design, evaluation and state-of-the-art

Date

Hanes

Ensign

2016

Journal of Controlled Release

397

192

View full text Add to dashboard Cite

The oral route is a preferred method of drug administration, though achieving effective drug delivery and minimizing off-target side effects is often challenging. Formulation into nanoparticles can improve drug stability in the harsh gastrointestinal (GI) tract environment, providing opportunities for targeting specific sites in the GI tract, increasing drug solubility and bioavailability, and providing sustained release in the GI tract. However, the unique and diverse physiology throughout the GI tract, including wide variation in pH, mucus that varies in thickness and structure, numerous cell types, and various physiological functions are both a barrier to effective delivery and an opportunity for nanoparticle design. Here, nanoparticle design aspects to improve delivery to particular sites in the GI tract are discussed. We then review new methods for evaluating oral nanoparticle formulations, including a short commentary on data interpretation and translation. Finally, the state-of-the-art in preclinical targeted nanoparticle design is reviewed.

show abstract

Section: Recent Developments In Targeting Oral Nanoparticles To Spsupporting

confidence: 52%

Nanoparticles for oral delivery: Design, evaluation and state-of-the-art

Date

Hanes

Ensign

2016

Journal of Controlled Release

397

192

View full text Add to dashboard Cite

show abstract

“…Prior to oral delivery of drug loaded NPs, 0.5 ml sodium bicarbonate solution was intragastrically administrated to neutralize the gastric acid [39,40]. Then the animals were administered by oral gavage with TNPs (50.0 IU/kg of insulin), P-T-NPs (50.0 IU/kg of insulin), insulin solution (50.0 IU/kg), or by subcutaneous injection (SC) with insulin solution (5.0 IU/kg).…”

Section: In Vivo Pharmacological and Pharmacokinetic Studiesmentioning

confidence: 99%

Efficient mucus permeation and tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles for oral insulin delivery

Liu

Zhang

Zhu

et al. 2016

Journal of Controlled Release

230

126

View full text Add to dashboard Cite

“…For permeability studies, a mixture of Caco-2 and HT29-MTX cells are seeded on semi-permeable polycarbonate Transwell filter inserts (Costar Transwell, Millipore Corp., Bedford, MA, USA) [ 8 , 37 , 58 ]. Predetermined cell numbers of Caco-2 and HT29-MTX cells are mixed prior to seeding to yield a specific ratio of Caco-2 to HT29-MTX cells.…”

Section: Developments Of In Vitro Methodsmentioning

confidence: 99%

“…Over the last few decades, the application of nanoparticles has been investigated for different routes of drug administration, which has opened up new possibilities for facing the shortcomings of current conventional dosage systems [ 5 ]. Although there have been tremendous innovations in different drug delivery systems, the oral route is still the most widespread and popular drug administration method by virtue of its convenience, low cost and high patient compliance compared with alternative routes [ 6 , 7 , 8 ]. However, the vulnerability of many drugs to the harsh conditions of the gastrointestinal (GI) tract and the possibility of chemical and enzymatic degradation results in poor therapeutic efficacy of many orally administered drugs [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Developments in Methods for Measuring the Intestinal Absorption of Nanoparticle-Bound Drugs

Liu

Pan

Zhang

et al. 2016

IJMS

View full text Add to dashboard Cite

With the rapid development of nanotechnology, novel drug delivery systems comprising orally administered nanoparticles (NPs) have been paid increasing attention in recent years. The bioavailability of orally administered drugs has significant influence on drug efficacy and therapeutic dosage, and it is therefore imperative that the intestinal absorption of oral NPs be investigated. This review examines the various literature on the oral absorption of polymeric NPs, and provides an overview of the intestinal absorption models that have been developed for the study of oral nanoparticles. Three major categories of models including a total of eight measurement methods are described in detail (in vitro: dialysis bag, rat gut sac, Ussing chamber, cell culture model; in situ: intestinal perfusion, intestinal loops, intestinal vascular cannulation; in vivo: the blood/urine drug concentration method), and the advantages and disadvantages of each method are contrasted and elucidated. In general, in vitro and in situ methods are relatively convenient but lack accuracy, while the in vivo method is troublesome but can provide a true reflection of drug absorption in vivo. This review summarizes the development of intestinal absorption experiments in recent years and provides a reference for the systematic study of the intestinal absorption of nanoparticle-bound drugs.

show abstract

The Glucose-Lowering Potential of Exenatide Delivered Orally via Goblet Cell- Targeting Nanoparticles

Abstract: CSK peptide-modified chitosan nanoparticles could be a potential therapeutics for Type II diabetes patients.

Cited by 33 publications

References 22 publications

Nanoparticles for oral delivery: Design, evaluation and state-of-the-art

Nanoparticles for oral delivery: Design, evaluation and state-of-the-art

Efficient mucus permeation and tight junction opening by dissociable “mucus-inert” agent coated trimethyl chitosan nanoparticles for oral insulin delivery

Developments in Methods for Measuring the Intestinal Absorption of Nanoparticle-Bound Drugs

Contact Info

Product

Resources

About